SEC Filing Summary for Acumen Pharmaceuticals, Inc.

On June 3, 2026, Porter Derrell, a director at Acumen Pharmaceuticals, Inc. (ABOS), acquired 35,500 shares of Common Stock through a restricted stock unit (RSU) award. These RSUs will vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, contingent upon Derrell's continued service. Additionally, Derrell was granted a stock option to purchase 53,250 shares of Common Stock, also vesting under the same conditions. The option has an exercise price of $2.29 and an expiration date of June 3, 2036. Following these transactions, Derrell owns 48,300 shares of Common Stock directly and has options for 53,250 shares.